Mirati Therapeutics
Mirati Therapeutics develops targeted therapies for cancer, focusing on genetic and immunological drivers, with a pipeline that includes drugs like adagrasib and sitravatinib.
Services
Mirati Therapeutics develops targeted therapies for the treatment of cancer, focusing on genetic and immunological drivers. The company offers investigational drugs and conducts clinical trials targeting KRAS mutations and other cancer-related molecular targets. Additionally, Mirati engages in collaborations with other pharmaceutical companies to enhance drug development. Mirati also offers an Expanded Access Program for the investigational drug adagrasib in Europe, the UK, and Switzerland for patients with KRASG12C-mutated cancers.
Products
The product pipeline of Mirati Therapeutics includes investigational drugs such as adagrasib, a KRASG12C inhibitor, and sitravatinib. Adagrasib is specifically designed to target KRASG12C mutations found in certain cancers. Sitravatinib targets a range of receptor tyrosine kinases implicated in cancer. These products are part of Mirati's efforts to address unmet medical needs in cancer treatment through advanced genetic and immunological research.
Collaborations
Mirati Therapeutics participates in multiple collaborations to advance drug development. Notable partnerships include collaborations with companies like Zai Lab, Sanofi, and Boehringer Ingelheim. These partnerships aim to leverage collective expertise and resources to accelerate the development and commercialization of novel cancer therapies.
Corporate Responsibility
Corporate responsibility is a key focus at Mirati Therapeutics. The company engages in initiatives centered on cancer research, education, and community support. Mirati Gives, the company's philanthropic arm, supports organizations working to improve cancer research and patient care. Mirati is committed to transparency and ethical conduct in all its business operations.